Novo aims to be ahead of pharma pack with Iran investment

DAVOS/LONDON (Reuters) - Danish drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan.